Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment
Condition(s):Advanced Gastric AdenocarcinomaLast Updated:December 30, 2019Completed
Hide Studies Not Open or Pending
Condition(s):Advanced Gastric AdenocarcinomaLast Updated:December 30, 2019Completed
Condition(s):Vascular Access DevicesLast Updated:June 1, 2023Not yet recruiting
Condition(s):Cardiopulmonary ResuscitationLast Updated:April 13, 2017Unknown status
Condition(s):Renal DialysisLast Updated:January 22, 2021Unknown status
Condition(s):DIVALast Updated:August 3, 2018Withdrawn
Condition(s):Difficult IV AccessLast Updated:June 6, 2008Completed
Condition(s):Encephalopathy, Hypoxic-Ischemic; Infant, Newborn, DiseasesLast Updated:September 17, 2021Recruiting
Condition(s):Hypovolemic Shock; Hemorrhagic ShockLast Updated:December 8, 2017Completed
Condition(s):Catheters; Catheterization, PeripheralLast Updated:November 4, 2019Completed
Condition(s):Drug EffectLast Updated:October 18, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.